Centanafadine SR is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 17 clinical trials, of which 11 were completed, and 6 are ongoing.

Centanafadine SR (EB-1020) acts as triple monoamine reuptake inhibitor that modulates norepinephrine (NE), dopamine (DA) and serotonin (5-HT) in a ratio of 1 to 6 to 14, respectively. This preferential NE with moderate DA reuptake inhibition profile, with a small amount of 5-HT reuptake inhibition, aids in the treatment for adult attention deficit hyperactivity disorder (ADHD). The drug candidate by inhibiting norepinephrine, serotonin and dopamine transporters alleviates the disease condition.

The revenue for Centanafadine SR is expected to reach a total of $666m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Centanafadine SR NPV Report.

Centanafadine SR was originated by Euthymics Bioscience and is currently owned by Otsuka Pharmaceutical. Otsuka Holdings is the other company associated in development or marketing of Centanafadine SR.

Centanafadine SR Overview

Centanafadine SR (EB-1020) is under development for the treatment of adult attention deficit hyperactivity disorder (ADHD), major depressive disorder and moderate to severe binge eating disorder (BED). It is a sustained-release (SR) formulation administered orally as a tablet and capsule. It acts by targeting norepinephrine, serotonin and dopamine transporters.

It was also under development for the treatment of smoking cessation

Otsuka Holdings Overview

Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.

The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020. The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.

Quick View – Centanafadine SR

Report Segments
  • Innovator
Drug Name
  • Centanafadine SR
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.